Stem Cell Therapy for Heart Failure
What is Heart Failure?
Heart failure is a condition in which the heart is not able to pump enough blood throughout the body for its normal function. The cause of this can be either functional or structural disorder of the heart. Common causes of heart failure include cardiomyopathy, hypertension, heart valve problems and coronary artery disease. There is no cure for heart failure.
Can stem cells help treat heart failure?
With respect to the heart, stem cells have the ability to not only home into the damaged areas but also to initiate a cascade of biological events which both culminate in healing of the heart muscle. For example, animal studies have demonstrated that stem cell therapy will cause new muscle cells to be formed through stimulation of dormant stem cells that are already inside the heart muscle. In these studies, the administered stem cell also transformed into new heart muscle cells.
At Stem Cell Institute, our stem cell treatment protocol for heart failure involves administration of mesenchymal stem cells harvested from human umbilical cord tissue.
Through administration of mesenchymal stem cells, we have observed improvements in heart failure patients treated at our facilities.
In a patient’s own words:
Which types of stem cells are used to treat heart failure and how are they collected?
The adult stem cells used to treat heart failure at the Stem Cell Institute come from human umbilical cord tissue (allogeneic mesenchymal). These stem cells are expanded at Medistem Panama’s state-of-the-art laboratory.
The mesenchymal stem cells we use are recovered from donated umbilical cords following normal, healthy births. Each mother has her medical history screened and is tested for infectious diseases. Proper consent is received from each family prior to donation.
All umbilical cord-derived stem cells are screened for infectious diseases to International Blood Bank Standards before they are cleared for use in patients.
Only a small percentage of donated umbilical cords pass our rigorous screening process.
Dr. Riordan on the Umbilical Cord Selection Process at Stem Cell Institute
“Through retrospective analysis of our cases, we’ve identified proteins and genes that allow us to screen several hundred umbilical cord donations to find the ones that we know are most effective. We only use these cells and we call them ‘golden cells’.
We go through a very high throughput screening process to find cells that we know have the best anti-inflammatory activity, the best immune modulating capacity, and the best ability to stimulate regeneration.”
What are the advantages of treating heart failure with allogeneic umbilical cord tissue-derived stem cells?
Since HUCT mesenchymal stem cells are immune system privileged, cell rejection is not an issue and Human Leukocyte Antigen (HLA) matching is not necessary.
The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
Umbilical cord tissue provides an abundant supply of mesenchymal stem cells.
No need to collect stem cells from the patient’s hip bone or fat under anesthesia, which especially for small children and their parents, can be an unpleasant ordeal.
There is a growing body of evidence showing that umbilical cord-derived mesenchymal stem cells are more robust than mesenchymal stem cells from other sources.
No need to administer chemotherapy drugs like Granulocyte-colony stimulating factor (G-CSF or GCSF) to stimulate the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Our mesenchymal stem cells and the US FDA: Are they approved?
Human umbilical cord tissue-derived mesenchymal stem cells (MSCs) that were isolated and grown in our laboratory in Panama to create master cell banks are currently being used in the United States under US FDA regulation.
These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient).
Will the patient reject this type of stem cell?
The body’s immune system is unable to recognize umbilical cord-derived mesenchymal stem cells as foreign and therefore they are not rejected. HUCT stem cells have been administered thousands of times at the Stem Cell Institute and there has never been a single instance rejection (graft vs. host disease). As a matter of fact, allogeneic (not the patient’s own) mesenchymal stem cells are approved to treat graft vs. host disease in Canada and New Zealand.
Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat and therefore, they are considered to be more “potent”.
In the words of an expert:
In this next video (just past the 1 minute mark), Arnold Caplan, PhD explains the mechanism by which donor mesenchymal stem cells shield themselves from the recipient’s immune system. Dr. Caplan is the scientist who discovered the mesenchymal stem cell. He is commonly referred to as “the father of the mesenchymal stem cell”.
How are the stem cells administered for heart failure treatment?
The umbilical cord-derived stem cells are administered intravenously by a licensed physician.
Stem Cell Treatment: Heart Failure *Protocols
Treatment protocol will be assigned by staff physicians after the patient has submitted all requested medical information and received approval. A patient’s recommended protocol may differ from the example given below.
Treatment duration: 4 days and 5 nights
Physical examination and blood testing: Monday
- 5 IV injections of expanded allogeneic (low-passage) mesenchymal stem cells
8 intramuscular injections of expanded allogeneic mesenchymal stem cells
2 IV Vitamin C infusion (depending on the patients renal function)
Stem-kine supplement for 1 month (only after medical evaluation in Panama)
*Includes Hilton hotel room with breakfast, WIFI, transportation from and to the airport with VIP airport gate service and expedited customs clearance upon arrival, and transportation between the Hilton and Stem Cell Institute.
Will someone from the Stem Cell Institute be following up with me after I return home?
Our medical staff will be contacting you at regular intervals to see how you are doing. Periodic follow-up also helps us evaluate overall treatment efficacy. Therefore, our medical staff will follow up with you after 1 month, 3 months, 6 months, and 1 year.
May I speak with any successfully treated heart failure patients?
Yes, you may. Once you have been evaluated and approved for treatment, your patient coordinator will be happy to put you in touch with treated heart failure patients who have volunteered to share their experiences in Panama with others.
You may also take a look at written testimonials, news articles and videos from some of our treated heart failure patients. Please take a look!
How do I request more information?
You may contact us by telephone 1 (800) 980-STEM (toll-free in US) and 1 (954) 358-3382.
Apply for treatment today
To apply for stem cell treatment, please complete this Patient Application Form.
Read Dr. Riordan’s new book about stem cell therapy today
Stem cells are the repair cells of your body. When there aren’t enough of them, or they aren’t working properly, chronic diseases can manifest and persist.
Neil H Riordan, PA, PhD, author of MSC: Clinical Evidence Leading Medicine’s Next Frontier, the definitive textbook on clinical stem cell therapy, brings you an easy-to-read book about how and why stem cells work, and why they’re the wave of the future.
From industry leaders, sport stars, and Hollywood icons to thousands of everyday, ordinary people, stem cell therapy has helped when standard medicine failed. Many of them had lost hope. These are their stories.
“Neil takes readers on a riveting journey through the past, present and future of stem cell therapy. His well-researched, educational and entertaining book could change your life. I highly recommend it.” – Tony Robbins, NY Times #1 Bestselling Author
Placental Mesenchymal and Cord Blood Stem Cell Therapy for Dilated Cardiomyopathy
Ichim T, Solano F, Brenes R, Glenn E, Chang J, Chan K, Riordan N.
– Reproductive BioMedicine Online 2008; 898-905
Combination of Stem Cell Therapy for Heart Failure
Ichim T, Solano F, Lara F, Paz Rodriguez J, Cristea O, Minev B, Ramos F, Woods E, Murphy M, Alexandrescu D, Patel A, Riordan N.– International Archives of Medicine 2010; 3:5